• The Promise And Perils Of Home-Use Tests

    Sep 21 | Diagnostics World News | The FDA’s regulatory process for home-use tests, including Emergency Use Authorizations (EUAs), and concerns surrounding in-home sample collection, were the focus of a series of talks at the recent Next Generation Dx Summit. While increasing access to testing, particularly during a pandemic, home-use tests come with significant challenges that include fairly weighing the risks and benefits, points out conference speaker Elliot Cowan, principal and founder of Partners in Diagnostics. More
  • CMR Imaging Of Athletes, Role For Thermography, Watch Pulse Oximeter Levels: COVID-19 Updates

    Sep 18 | Diagnostics World News | Differing nasal expressions in blacks, a risk stratification tool for athletes, a new antibody test for identifying plasma donors, warning for patients with sleep apnea, the utility of infrared thermographs, lower pulse oximetry levels and fever lead reasons for rehospitalizations, and a Lab-in-Cartridge device rolling out across the U.K. Plus, a dual-purpose nonprofit, computing how to allocate test kits, seven digital health solutions receive NIH funding, and efforts underway to standardize SARS-CoV-2 assays. More
  • Diagnostic Stewardship: Better Care At A Lower Cost

    Sep 16 | Diagnostics World News | Diagnostic stewardship was a trending topic at the recent Next Generation Dx Summit, and the highlights included presentations by Christopher Doern, director of clinical microbiology at Virginia Commonwealth University (VCU) Health System and the Medical College of Virginia, and Matt Binnicker, director of clinical virology and vice chair of practice in the department of laboratory medicine and pathology at the Mayo Clinic. Both offered practical advice and tips for improving patient care under real-world budget and workforce constraints. More
  • Follow the Money: Cancer Blood Tests, Regulatory Information Management

    Sep 14 | Diagnostics World News | Big money for Freenome’s colorectal cancer blood test, investments in the Regulatory Information Management market, and more. More
  • Antibody Test-On-A-Chip, New Mortality Score, Chest X-Rays In Diagnostics: COVID-19 Updates

    Sep 11 | Diagnostics World News| Harvard researchers have optimized new SARS-CoV-2 diagnostic, antibody test-on-a-chip uses gold nanospikes for virus detection, 4C Mortality Score predicts disease outcome, and LSU radiologists argue for chest x-rays in COVID-19 diagnostics. Plus, scaled up testing, AI-powered reopening, more testing receives EUAs. More
  • Post-Pandemic, Payers May Be Reining In Telemedicine

    Sep 10 | Diagnostics World News | Telemedicine is probably not appreciably lowering the overall cost of patient care, according to Maria Turner, managing director at global management consulting firm AArete. Post-pandemic, Turner expects the telemedicine landscape will look a lot different than it does today. More
  • Moving From Why To How With Personalized Medicine Technologies

    Sep 08 | Diagnostics WorldOncologists often make decisions about diagnostic tests with very little information to go on, and the dearth of high-quality evidence has made it difficult for both doctors and institutions to advance personalized medicine without a roadmap for overcoming the challenges, which the Personalized Medicine Coalition (PMC) has been developing. At the recent Next Generation Dx Summit, speakers explored how oncologists choose and evaluate such tests. More
  • Speed To Answers, Viral Spreaders, Symptom Data Challenge: COVID-19 Updates

    Sep 04 | Diagnostics World News | A CRISPR-based assay and smartphone-based molecular test, the role of children in viral spread, using pressure to concentrate samples, a patient scoring system, timetable on retesting, two tests are better than one, and deep dives on older patients. Plus, the COVID-19 Symptom Data Challenge and nine more companies get NIH grants to scale up COVID-19 testing. More
  • Rules of the Regulatory Road For Companion Diagnostics

    Sep 01 | Diagnostics World News | The regulatory framework around drug and diagnostic co-development, and how to overcome the inevitable hurdles, was the subject of multiple presentations at the 12th Annual Next Generation Dx Summit held virtually last week. More
  • Racial Impacts, Inflammation Markers, Two New Saliva Tests: COVID-19 Updates

    Aug 28 | Diagnostics World News | Census data shows COVID-19 follows HIV patterns of racial segregation, how virtual imaging studies can help, inflammation markers that predict severe disease, and models of early transmission. Plus, two EUAs for saliva tests and back-to-work testing. More
View more articles



Antigens & Antibodies for SARS-CoV-2 Diagnostic Kit Development

ACROBiosystems team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of high-quality antigen and antibody reagents to support the development of the diagnostic kits. The products include the high quality S trimer, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity tested on several platforms.

Click to learn more about ACRO’s hot matched antibody pairs and antigens.


2020 Global Coronavirus Diagnostics Market

The report presents a detailed analysis of the Coronavirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Coronavirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: Hospitals, Commercial/Private Labs, Physician Offices and Public Health Labs.

Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals. The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyze and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic deal making market.